Does Coffee Lower the Risk of Endometrial Cancer?

Article

Drinking coffee multiple times a day may decrease the risk of endometrial cancer in women, according to a new study.

Women who drank three cups of coffee per day had a lower risk of endometrial cancer. Photo © topseller/Shutterstock.com.

Drinking coffee multiple times a day may decrease the risk of endometrial cancer in women, according to a new study. Using dietary questionnaire results from three prospective studies on 84 different foods, the authors found that coffee intake was inversely associated with endometrial cancer risk.

In one of the studies, women who drank three cups of coffee per day-about 750 grams-had a 19% lower risk of endometrial cancer compared with women who drank less than one cup of coffee per day. Data from a different study cohort found that those who drank four cups of coffee per day-about 1,000 grams-had an 18% lower risk of endometrial cancer compared with those who did not drink coffee.

The results were published in Cancer Epidemiology, Biomarkers & Prevention.

Melissa A. Merritt, PhD, a statistician at the School of Public Health at Imperial College London in the United Kingdom, and colleagues assessed whether 84 nutrients and foods could be linked to endometrial cancer risk, using dietary questionnaires completed by 301,107 women who were between the ages of 25 and 70 at enrollment in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Of these women, 1,303 developed endometrial cancer.

From the EPIC study data, 10 foods and nutrients were found to have some association with a risk of endometrial cancer. An increased risk was associated with butter, yogurt, potatoes, and carbohydrates, while a decreased risk was associated with cheese, coffee, cream desserts, total fat, monounsaturated fat, and phosphorus.

The links between these foods and endometrial cancer risk were then further validated using a cohort of women who were part of the Nurses’ Health Study (NHS) and NHS II, from the Brigham and Women’s Hospital and Harvard School of Public Health, respectively. A total of 1,531 cases of endometrial cancer were reported from this cohort.

Only the links with butter and coffee were validated in the NHS cohort. Coffee has previously been linked to a decreased risk of endometrial cancer in both an NHS study and two prior meta-analyses.

It is not clear which components of coffee may be beneficial. One hypothesis is that coffee may be related to decreased C-peptide levels, a marker of reduced insulin secretion, which may lower exposure to estrogen and therefore obesity, said the authors in their discussion. Other studies have shown that increased intake of both caffeine and caffeine-containing coffee results in increased adiponectin levels, which is associated with lower insulin sensitivity and a decrease in estrogen levels. But, non-caffeine coffee components have also been implicated in cancer risk reduction.

“Coffee intake is worth investigating further to see if coffee can be used for the prevention of endometrial cancer. However, before clinical recommendations can be made, further studies are needed to evaluate this question in other studies and to try to isolate the components of coffee that may be responsible for any influence on endometrial cancer,” said Merritt in a statement.

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.
The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.
Related Content